Overview

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Status:
Not yet recruiting
Trial end date:
2026-02-17
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company